A multi-enzyme cascade antioxidant nano HOF and preparation method and application thereof are provided. The present invention discloses a nano HOF based on selenium-containing ligand for the first time, the nano HOF does not contain metal and has good biocompatibility, which is a universal loading platform, and has high porosity, acid and alkali resistance and thermal stability, and is size-tunable, it can coat various types of enzymes at the same time, stabilize the conformation of the enzyme through the confinement effect, the high porosity can not only provide enough space for the enzyme, but also facilitate the transport of substances and the play of catalytic properties of the enzyme, 85-90% of the activity of the coated enzyme can be maintained, ROS can be effectively scavenged through the cascade catalysis between various enzymes, which provides a new idea for the construction of bio-friendly antioxidants.
C07C 391/02 - Compounds containing selenium having selenium atoms bound to carbon atoms of six-membered aromatic rings
C07C 257/18 - Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
Provided is a method for preparing fluralaner. The method includes: mixing 4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-isoxazol-3-yl)-2-methyl-benzoic acid, a catalyst, an alcohol and an organic solvent to obtain a mixture, and subjecting the mixture to esterification to obtain an esterification solution containing 4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-isoxazol-3-yl)-2-methyl-benzoate; and mixing the esterification solution with 2-amino-N-(2,2,2-trifluoroethyl)acetamide to obtain a mixed solution and subjecting the mixed solution to ester decomposition-amidation to obtain the fluralaner.
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
3.
VINYLATION COUPLED DERIVATIVE OF BETA-ELEMENE, AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG
The present disclosure provides a vinylation coupled derivative of β-elemene, and a preparation method and use thereof in preparation of an antitumor drug. The present disclosure provides a vinylation coupled derivative of β-elemene having a structure shown in Formula (I), a pharmaceutical composition and a hydrate including a compound shown in Formula (I), as well as an isotopic derivative, a chiral isomer, a variant, a salt, a prodrug, and a preparation of the compound shown in Formula (I). The present disclosure further provides a preparation method and use of the vinylation coupled derivative of β-elemene, and an inhibitory activity of the derivative on proliferation of various tumor cell lines. The vinylation coupled derivative of β-elemene is expected to be an antitumor drug candidate for treating colon cancer and lung cancer.
The present disclosure provides a vinylation coupled derivative of β-elemene, and a preparation method and use thereof in preparation of an antitumor drug. The present disclosure provides a vinylation coupled derivative of β-elemene having a structure shown in Formula (I), a pharmaceutical composition and a hydrate including a compound shown in Formula (I), as well as an isotopic derivative, a chiral isomer, a variant, a salt, a prodrug, and a preparation of the compound shown in Formula (I). The present disclosure further provides a preparation method and use of the vinylation coupled derivative of β-elemene, and an inhibitory activity of the derivative on proliferation of various tumor cell lines. The vinylation coupled derivative of β-elemene is expected to be an antitumor drug candidate for treating colon cancer and lung cancer.
A monitoring and early warning device for preventing falling during getting up of old people is provided by the disclosure, relating to safety protection for the old people. The device includes a bedstead mechanism, a lifting auxiliary mechanism is arranged at the top of the bedstead mechanism. When the motion sensor monitors an instantaneous acceleration behavior, it's judged that the old people fall; when the TOF radar detects a long-term static behavior of the old people in the external area of the device, it's judged that the old people drop. Abnormal behavior activates the acousto-optic alarm and sends early warnings to intelligent terminals of accompanying personnel and medical staff through a built-in module for warning. Staff unable to offer immediate help could turn on the camera to watch the image information near the device through the intelligent terminal at this time, and take actions based on the old people's condition.
A61G 7/10 - Devices for lifting patients or disabled persons, e.g. special adaptations of hoists thereto
G08B 21/04 - Alarms for ensuring the safety of persons responsive to non-activity, e.g. of elderly persons
5.
Linear boron-dipyrromethene electron donor having 180° coordination included angle and supramolecular metal macro-ring, and synthesis processes therefor and applications thereof
Disclosed are a linear boron-dipyrromethene electron donor having a 180° coordination included angle and a supramolecular metallacycle, and synthesis processes therefor and applications thereof. The invention provides a linear boron-dipyrromethene electron donor as shown in formula 3 or formula 4, and a boron-dipyrromethene ligand-based supramolecular coordination compound having a 180° coordination included angle which is prepared by the metal coordination of the linear boron-dipyrromethene electron donor. Compared with a prepolymer, the boron-dipyrromethene ligand-based supramolecular coordination compound has better cell passive uptake capacity, cell fluorescence imaging capacity and photosensitive (singlet oxygen generation) capability.
A dual-modal information storage and anti-counterfeiting material, and its preparation method are provided. The dual-modal information storage and anti-counterfeiting material uses cadmium sulfide quantum dots (CdS QDs) as information storage material, and uses the controllable photocorrosion of CdS QDs to achieve dual-modal optical information storage and anti-counterfeiting applications. Firstly, the type of ligands and modification degree of CdS QDs are precisely controlled during the aqueous phase synthesise process, so as to effectively control the photocorrosion phenomenon under UV light irradiation. Subsequently, the CdS QDs are loaded in the hydrogel network, and they are also loaded on the substrates such as cloth and paper by spray coating, dip coating or 3D printing, and the information is stored by digital light patterning. Different from the photochromic function of traditional anti-counterfeiting material, the CdS QDs shows dual-modal patterning characteristics in a wide wavelength range.
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
A nano-formulation, a preparation method therefor, and use thereof. The nano-formulation is prepared by loading an anti-cancer drug β-elemene by a DSPE-PEG-coated stanene nanosheet (STNSP). The STNSP and β-elemene can effectively polarize tumor-promoting M2 tumor-associated macrophages (TAMs) into a tumor-suppressive M1 phenotype by means of activating an active oxygen-related signaling pathway, that is, an immune cell population is activated by means of inducing M2-to-M1 polarization of the TAMs, thereby triggering an anti-tumor immune response. The STNSP and β-elemene also have a synergistic effect, so that B16F10 melanoma cells can be selectively killed, thereby enhancing the anti-tumor efficacy.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A continuous boiling water preparation method based on gas-liquid two-phase object detection comprises a flow regulator, a heater, a temperature sensor, a two-phase object detection sensor and a controller; the flow regulator is used for injecting a cold water flow obtained from the outside into a water inlet of the heater; the heater heats up according to heating power provided by the controller; the two-phase object detection sensor and the temperature sensor are connected behind a water outlet of the heater, and when a boiling water flow flows through the two sensors, a gas-liquid ratio signal and a temperature signal are obtained respectively, and transmitted to the controller; and the controller transmits a signal indicating required heating power to the heater or transmits a signal indicating a required flow value to the flow regulator through calculation to execute output after receiving the gas-liquid ratio signal.
The present disclosure provides a dual-targeting biomimetic liposome with elemene (ELE) and cabazitaxel (CTX), where each 100 mL of the dual-targeting biomimetic liposome with ELE and CTX includes 0.15 g to 0.75 g of the ELE, 0.5 mL to 2.5 mL of absolute ethanol, 0.015 g to 0.07 g of the CTX, 0.25 g to 1 g of oil, 0.25 g to 1 g of a polyethylene glycol (PEG) derivative, 1 g to 5 g of a phospholipid, 0.05 g to 0.2 g of cholesterol, 0.025 g to 0.1 g of distearoyl phosphatidylethanolamine-polyethylene glycol 2000-transferrin (DSPE-PEG2000-Tf), 0.005 g to 0.025 g of a tumor cell membrane protein (CMP), and water as a balance.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
Disclosed are an abietane type diterpene compound, a preparation method and an application thereof, relating to the technical field of anti-tumor compounds, where the compound has a chemical structure as shown in the following formula I:
Leucosceptrum canum is extracted to prepare the abietane type diterpene compound according to the present application, and the prepared compound is effectively applied in inhibiting human lung cancer cell A549 and human myeloid leukemia cell HL-60.
C07C 49/747 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups containing six-membered aromatic rings
A61P 35/02 - Antineoplastic agents specific for leukemia
C07C 45/79 - SeparationPurificationStabilisationUse of additives by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by chemisorption
11.
LIQUID VINYL FUNCTIONALIZED CAGE-TYPE POLYHEDRAL OLIGOMERIC SILSESQUIOXANE MODIFIED BY LOW-MOLECULAR-WEIGHT POLYSILOXANE AND PREPARATION METHOD THEREOF
Disclosed are liquid vinyl functionalized cage-type polyhedral oligomeric silsesquioxane modified by low-molecular-weight polysiloxane and a preparation method thereof. Under the catalytic action of tris(pentafluorophenyl)borane, cage-type octakis (dimethylsiloxy)-T8-silsesquioxane and hetero telechelic polydimethylsiloxane undergo a Piers-Rubinsztajn reaction, to obtain liquid Vi-POSS. Side chains of the liquid vinyl functionalized POSS in the present disclosure are Si—O—Si chain links, have better heat stability than that of common long-carbon-chain side chains, and contain vinyl functional groups capable of participating in chemical reactions, which not only have good mechanical enhancement and heat resistance properties, but also have chemical reactivity.
The disclosure relates to the field of medicinal chemistry. Disclosed are a 14-chloro-β-elemene nitric oxide donor derivative and a preparation method and use thereof in the preparation of anti-tumor drugs. The 14-chloro-β-elemene nitric oxide donor derivative has a general formula shown in formula (I): in formula (I): R1 represents a linear or cyclic alcohol amine structure containing nitrogen and oxygen atoms; and each of R2 and R3 is independently selected from the group consisting of C1-10 alkyl, C3-12 cycloalkyl, C6-12 aryl, 5- to 10-membered cyclic heteroaryl, C2-10 alkenyl, C2-10 alkynyl, and C2-10 alkoxy. In the disclosure, the derivative is superior to the previous β-elemene nitric oxide donor derivatives in terms of the design strategy, an alcohol amine structure that can enhance in vivo anti-tumor activity is introduced as a linker, which improves in vivo stability, and provides good therapeutic activity against malignant brain glioma against which effective therapeutic drugs is short in clinical practice.
The disclosure relates to the field of medicinal chemistry. Disclosed are a 14-chloro-β-elemene nitric oxide donor derivative and a preparation method and use thereof in the preparation of anti-tumor drugs. The 14-chloro-β-elemene nitric oxide donor derivative has a general formula shown in formula (I): in formula (I): R1 represents a linear or cyclic alcohol amine structure containing nitrogen and oxygen atoms; and each of R2 and R3 is independently selected from the group consisting of C1-10 alkyl, C3-12 cycloalkyl, C6-12 aryl, 5- to 10-membered cyclic heteroaryl, C2-10 alkenyl, C2-10 alkynyl, and C2-10 alkoxy. In the disclosure, the derivative is superior to the previous β-elemene nitric oxide donor derivatives in terms of the design strategy, an alcohol amine structure that can enhance in vivo anti-tumor activity is introduced as a linker, which improves in vivo stability, and provides good therapeutic activity against malignant brain glioma against which effective therapeutic drugs is short in clinical practice.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Disclosed are a cocaine esterase mutant and use thereof. The cocaine esterase mutant is obtained by mutating a wildtype cocaine esterase, an amino acid sequence of the wildtype cocaine esterase is shown as SEQ ID No. 1, the cocaine esterase mutant is T172R/G173Q/L196C/I301C, or additionally added with V116K point mutation, or additionally added with A51 site mutation, and the A51 site mutation is L, Y, V, F or W. Catalytic efficiency of the cocaine esterase mutant screened on a cocaine toxic metabolite benzoylecgonine is greatly improved compared with that of a wildtype enzyme.
The present invention provides a β-elemene derivative containing the photoaffinity group diazirine, a preparation method therefor, and use thereof as a photoaffinity molecular probe. The present invention provides a compound of a structure represented by general formula (I), a pharmaceutical composition and a hydrate comprising the compound of general formula (I), and an isotopic derivative, a chiral isomer, a variant, different salts, a prodrug, a formulation, etc. of the compound. Further disclosed herein are a preparation method for the β-elemene derivative containing the photoaffinity group diazirine and use, and the antiproliferative activity of the compound against various tumor cell strains, and the compound is used in β-elemene interaction protein screening. The β-elemene photoaffinity molecular probe in the present invention is expected to become a molecular tool for elemene target screening and studies on the mechanism of action.
C07D 203/04 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
A traffic accident forensics method based on a blockchain is provided. After a traffic accident, the method allows vehicles to carry out a mutual verification and sign a respective accident report. After one of the vehicles verifies with a road side unit, the signed accident report is submitted to the road side unit and uploaded to the blockchain, so as to record the accident report and preventing the accident report from being tampered, and an efficient mutual verification between the vehicle and the road side unit is achieved. The key parameters in the mutual verification process are encrypted based on an elliptic curve algorithm, and thus the security of the whole mutual verification process is improved. A batch verification way for signatures is designed to reduce the compute pressure of a wireless device. Vehicles use dynamic anonymity policies to protect privacy in the forensics method.
A CpG liposome of the present invention is modified with folic acid on the surface and is loaded with CpG. Every 100 parts of the CpG liposome comprises, by weight, 1-5 parts of phospholipid, 0.04-0.2 parts of cholesterol, 0.004-0.1 parts of a polyethylene glycol derivative, 0.02-0.1 parts of DSPE-PEG-folic acid, 0.004-0.1 parts of CpG, and the balance of water. An ELE liposome is modified with folic acid and AS1411 on the surface and is loaded with elemene. Every 100 parts of the ELE liposome comprises, by weight, 1-5 parts of phospholipid, 0.04-0.2 parts of cholesterol, 0.004-0.1 parts of a polyethylene glycol derivative, 0.15-0.75 parts of ELE, 0.02-0.1 parts of DSPE-PEG-folic acid, 0.0005-0.002 parts of cholesterol-AS1411, and the balance of water. The combined use of the CpG liposome and the ELE liposome can inhibit the growth of tumors and reverse the tumor immune microenvironment by means of a synergistic effect.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A method for inter-hospital identity authentication and electronic medical record transfer of patients is provided. Based on a blockchain technology, a patient achieves secure and efficient inter-hospital transfer authentication, and a new hospital accesses an electronic medical record with authorization of the patient, thus achieving reliable electronic medical record access controls. In each hospital, the patient, a medical server, and a doctor achieve efficient tripartite authentication and negotiation of session keys, and communicate based on the session keys. By introducing an elliptic curve to encrypt key parameters in an authentication process, a security of the entire authentication process is improved, and a computational pressure on a wireless device is reduced. In the authentication and the electronic medical record, the patient uses dynamic anonymity policies to protect privacy.
G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
H04L 9/00 - Arrangements for secret or secure communicationsNetwork security protocols
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
18.
Application of hydrophobic phthalocyanine as heterogeneous catalyst in oxidizing phenol wastewater by hydrogen peroxide
2 as an oxidant into the phenol wastewater. The hydrophobic phthalocyanine is obtained by decorating a hydrophobic group on a bacterial cellulose-metal phthalocyanine with a silane coupling agent; the bacterial cellulose-metal phthalocyanine is obtained by mixing a metal phthalocyanine into a bacterial cellulose medium, biologically culturing with an acetic acid bacterium, and then heating and reducing the mixture; and the metal phthalocyanine is nitro-sulfonic metal phthalocyanine.
C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
The present disclosure provides a room-temperature-vulcanizing (RTV) silicone rubber foam with ablation resistance and high-efficiency heat insulation and a preparation method thereof. In the present disclosure, hydroxyl-terminated polydimethylsiloxane, vinyl-terminated polydimethylsiloxane, a catalyst, an inhibitor, a ceramifiable emulsion foaming agent, a functionalized ceramic filler, and a heat-resistant additive are placed in a planetary stirring tank, and stirred to obtain a base rubber A. The hydroxyl-terminated polydimethylsiloxane, the vinyl-terminated polydimethylsiloxane, a hydrogen-containing silicone oil, a functionalized low-melting glass powder, and functionalized hexagonal boron nitride are placed in the planetary stirring tank, and stirred to obtain a base rubber B. The base rubber B is transferred to the base rubber A, vulcanization is conducted, followed by after vulcanization in an oven to obtain a final product.
Disclosed are a cis-platinum cross-linked protein hydrogel and a preparation method thereof. Main components of the cis-platinum cross-linked protein hydrogel comprise the following ingredients in percentage by mass: 0.5% to 5.0% drug, 6.0% to 50.0% serum albumin and 47.0% to 93.0% solvent medium; a carboxyl group on a surface of the serum albumin and the drug form a coordinate bond; and the drug is cis-platinum. A hydrogel preparation is simple in structure and easy to prepare, and the used cis-platinum has dual effects: a cross-linking agent for promoting the formation of protein hydrogels and an antitumor drug for exerting a tumor inhibition curative effect. The strategy simplifies the carrier design and reduces potential toxic side effects. The protein carboxyl limits the release of cis-platinum through a coordination effect so that reduce the burst release of the loaded drugs drastically.
The present invention belongs to the technical field of medicine. Disclosed is use of a pharmaceutical combination of β-elemene and osimertinib in the preparation of an anti-lung cancer medicament. Disclosed is a pharmaceutical composition, comprising β-elemene and osimertinib. Further disclosed is use of the pharmaceutical composition in the preparation of an anti-tumor pharmaceutical combination by means of inhibiting the process of IGF1R/vimentin/EMT. In the pharmaceutical composition for inhibiting the IGF1R/vimentin/EMT, one medicament can be bound with IGF1R and inhibit its activity, and is used in combination with another medicament to synergistically inhibit the activity of vimentin, thereby inhibiting EMT and achieving a synergistic anti-tumor effect. Vimentin is a key intermediate regulation point for IGF1R to inhibit EMT. When the medicament targeting IGF1R selects a combined medicament, the inhibition of EMT induced by vimentin reduction can be used as a new effect target path for screening the combined medicament.
A contactless vital signs monitoring system is installed on a mattress and includes a contactless vital signs signal acquisition and processing system. The contactless vital signs signal acquisition and processing system includes a BCG signal acquisition module, a human body pressure acquisition module and a control circuit. A piezoelectric ceramic array is arranged on the mattress to serve as the BCG signal acquisition module, a resistance-type pressure belt is arranged on the mattress to serve as the human body pressure acquisition module, and in combination with an intelligent dynamic wave peak tracing algorithm, heart rate data, respiration data, body movement data, on-bed/off-bed condition and abnormal sound data of a user in a sleep process can be extracted, and a sleep condition of the user can be comprehensively analyzed. The contactless vital signs monitoring system operates in an intelligent ultralow power consumption operation control mode, thus energy consumption is greatly reduced.
A non-contact vital sign monitoring system, mounted on a mattress, and comprising a non-contact vital sign signal acquisition and processing system. The non-contact vital sign signal acquisition and processing system comprises a BCG signal acquisition module, a human body pressure acquisition module and a control module. A piezoelectric ceramic chip array is arranged on the mattress as the BCG signal acquisition module, and an impedance pressure belt is arranged as the human body pressure acquisition module, such that in cooperation with an intelligent dynamic wave peak tracing algorithm, heart rate data, breathing data, body movement data, in/out of bed conditions and abnormal sound data of a user in the sleep process can be extracted, so that the sleep condition of a user can be comprehensively analyzed. The system runs in an intelligent ultra-micro power working control mode, and when the pressure data measured by the human body pressure acquisition module indicates that the user is not on the bed, the non-contact vital sign monitoring system turns off most power utilization elements, so that the energy consumption is greatly reduced.
Provided are a Curcuma wenyujin Y. H. Chen & C. Ling-derived curcumin synthetase, a gene, a vector, an engineered bacterium, and use thereof. The amino acid sequence of the curcumin synthetase is set forth in SEQ. ID NO. 2. The sequence of the coding gene of said curcumin synthetase is set forth in SEQ. ID NO. 1. The constructed recombinant vector is pYES2::CwPKS. The recombinant genetically engineered bacterium is Saccharomyces cerevisiae BY4741/pESC::LEU::At4CL-CIDCS/pYES2::CwPKS. The genetically engineered bacterium has the ability to produce curcumin using ferulic acid, produce mono-demethoxycurcumin using ferulic acid and coumaric acid, and produce tetrahydrobisdemethoxycurcumin using dihydrocoumaric acid. A catalyst can be quickly and massively prepared in yeast cells for use in large-scale synthesis of curcumin compounds.
Disclosed are a BODIPY-based diamond-shaped metal ring, and a method for preparing same, and use thereof in near-infrared emission. According to the present invention, a BODIPY-based 120-degree bipyridine BODIPY ligand molecule 1 having near-infrared I window absorption and a 60-degree methoxy platinum receptor molecule 2 self-assemble by means of Pt-N metal coordinate bonds to form the BODIPY-based diamond-shaped metal ring M. The BODIPY-based diamond-shaped supermolecule metal ring has good solubility and near-infrared fluorescence emission performance. By wrapping the metal ring with a commercial amphiphilic polymer carrier F127, the present invention provides an F127/M nanoparticle having excellent efficacy in photodynamic therapy and photothermal therapy in vitro.
Green synthesis method of antibacterial super-porous hydrogel, product of antibacterial super-porous hydrogel and application of antibacterial super-porous hydrogel to degradation of various pollutants in wastewater treatment
Disclosed are a green synthesis method of an antibacterial super-porous hydrogel, a product of the antibacterial super-porous hydrogel and an application of the antibacterial super-porous hydrogel to degradation of various pollutants in wastewater treatment. The super-porous hydrogel based on poly (ionic liquid) is prepared by copolymerization of an imidazole type ionic liquid with double bonds and polyethylene glycol diacrylate (PEGDA) as a cross-linker. In the reaction system, water is a good solvent for the monomer ionic liquid and PEGDA, but a poor solvent for the poly (ionic liquid); when an initial concentration of the ionic liquid is higher than 25%, the phase separation typically proceeds through poly(ionic liquid) formation, interconnected networks with macroporous structure could be obtained by photo-crosslinking.
C08F 2/50 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light with sensitising agents
C08F 283/06 - Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass on to polyethers, polyoxymethylenes or polyacetals
C08G 61/04 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
A continuous boiling water preparation system and a preparation method, based on gas-liquid two-phase object detection. The preparation system comprises a flow regulator (1), a heater (2), a temperature sensor (4), a two-phase object detection sensor (5), and a controller (3); the flow regulator (1) is used to inject a cold water flow obtained from outside into a water inlet of the heater (2); the heater (2) heats up according to heating power provided by the controller (3); the two-phase object detection sensor (5) and the temperature sensor (4) are connected behind the water outlet of the heater (2), and when a boiling water flow flows through the two-phase object detection sensor (5) and the temperature sensor (4), a gas-liquid ratio signal and a temperature signal, respectively, are obtained and transmitted to the controller (3); the controller (3), upon receiving the gas-liquid ratio signal, transmits a signal indicating a required heating power to the heater (2), or transmits a signal indicating a required flow value to the flow regulator (1), to execute output. The gas-liquid ratio signal serves as a closed-loop feedback signal in the continuous preparation of boiling water, ensuring that the user receives actually boiling water while retaining the advantages of current rapid-heating water dispensers.
A β-elemene vinylation coupled derivative, and a preparation method therefor and the use thereof in the preparation of an antitumor drug. Provided are a β-elemene vinylation coupled derivative having a structure as represented by formula (I), a pharmaceutical composition and a hydrate containing a compound of formula (I), and an isotopic derivative, a chiral isomer, an allosteric substance, a salt, a prodrug, a preparation, etc., of the compounds. Further provided are a method for preparing the β-elemene vinylation coupled derivative, the use thereof, and the inhibitory activity of the compounds on the proliferation of various tumor cell lines. The β-elemene vinylation coupled derivative is expected to be an antitumor drug candidate for the treatment of colon cancer and lung cancer.
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
C07C 69/767 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring esterified with unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
C07C 67/343 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton by increase in the number of carbon atoms
C07C 255/50 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
C07C 22/08 - Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
C07C 17/263 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
C07C 25/24 - Halogenated aromatic hydrocarbons with unsaturated side chains
C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
C07C 13/28 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 213/73 - Unsubstituted amino or imino radicals
C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 295/033 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
C07D 295/205 - Radicals derived from carbonic acid
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
C07B 37/00 - Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Disclosed in the present invention are a β-elemene derivative with an HDACi pharmacophore, and a preparation method therefor and the use thereof. Provided in the present invention are a β-elemene derivative with an HDACi pharmacophore having a structure as represented by formula (I), a pharmaceutical composition and hydrate containing a compound of formula (I), and an isotopic derivative, a chiral isomer, an allosteric substance, different salts, a prodrug, a preparation, etc., of the compounds. Further provided in the present invention are a method for preparing the β-elemene derivative with the HDACi pharmacophore, the use thereof, and the inhibitory activity of the compound on the proliferation of various tumor cell lines. The β-elemene derivative with the HDACi pharmacophore in the present invention is expected to become an antitumor drug candidate for treating various cancers, such as solid tumors and hematological tumors.
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 213/78 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Disclosed are a β‑Elemene derivative containing an N-OH bond, a preparation method therefor and a use thereof. The present invention provides a class of β‑Elemene derivatives containing an N-OH bond having the structure shown in formula (I), pharmaceutical compositions containing the compounds of formula (I) and hydrates, as well as isotope derivatives, chiral isomers, variants, different salts, prodrugs, formulations and the like of these compounds. The present invention also provides a preparation method for and a use of the class of β‑Elemene derivatives containing an N-OH bond and the activity of the compounds on proliferation inhibition of various tumor cell strains. The class of β‑Elemene derivatives containing an N-OH bond in the present invention is expected to become an anti-tumor candidate drug for treating lung cancer.
C07D 213/73 - Unsubstituted amino or imino radicals
C07D 213/54 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 213/78 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
C07D 317/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
31.
LINEAR BODIPY ELECTRON DONOR HAVING 180º COORDINATION INCLUDED ANGLE AND SUPRAMOLECULAR METAL MACRO-RING, AND SYNTHESIS PROCESSES THEREFOR AND USE THEREOF
The present invention discloses a linear BODIPY electron donor having a 180º coordination included angle and a supramolecular metal macro-ring, and synthesis processes therefor and the use thereof. The present invention provides the linear BODIPY electron donor as shown in formula 3 or formula 4, and a BODIPY ligand-based supramolecular coordination compound having a 180º coordination included angle and prepared by means of the metal coordination of the linear BODIPY electron donor. Compared with a prepolymer, the BODIPY ligand-based supramolecular coordination compound has better passive cell uptake capacity, fluorescence cell imaging capacity and photosensitive (singlet oxygen generation) capability
The present disclosure proposes a BODIPY-based rhombic metal ring, its preparation method, and application in near-infrared region imaging, specifically a BODIPY-based rhombic metal ring M absorbed in the near-infrared first region formed based on a BODIPY-based 120° bipyridyl BODIPY ligand molecule 1 and a 60° methoxy platinum acceptor molecule 2, self-assembled by Pt—N metal coordination bonds. The BODIPY-based rhombic supramolecular metal ring has good solubility and near-infrared fluorescence emission, and it is wrapped by commercial amphiphilic polymer F127 carrier to form F127/M nanoparticles, which successfully have excellent photodynamic and photothermal therapeutic effects in vitro.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
33.
Application of hydrophobic phthalocyanine as heterogeneous catalyst in oxidizing phenol wastewater by hydrogen peroxide
Disclosed is an application of a hydrophobic phthalocyanine as a heterogeneous catalyst in oxidizing phenol wastewater by hydrogen peroxide. A hydrophobic silane is decorated on a bacterial cellulose-metal phthalocyanine heterogeneous catalyst to obtain a hydrophobic phthalocyanine heterogeneous catalyst; during the catalytic degradation of phenols, the obtained catalyst is capable of adjusting a concentration of hydrogen peroxide oxidant around the catalyst. A preparation method of the hydrophobic phthalocyanine comprises: 1. preparing a mixed solution of a bacterial cellulose medium containing metal phthalocyanine; 2. adding acetic acid bacterium into the mixed solution obtained in step 1 for biological culture; 3. heating the product obtained in step 2, and taking out a solid for cleaning and drying; 4. preparing a hydrophobic silane solution; and 5. immersing the product obtained in step 3 into the solution obtained in step 4, and taking out a solid after reaction for cleaning and drying.
C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
Disclosed are a bacillus strain WYJ-E14 isolated from curcuma wenyujin Y. H. Chen & C. Ling and use thereof in the preparation of an anti-tumor drug. An endophyte isolated from a rhizome part of curcuma wenyujin Y. H. Chen & C. Ling belongs to bacillus velezensis. Bacillus velezensis is widely distributed in nature, has good characteristics of rapid growth and genetic stability, is harmless to human beings and animals, and does not pollute the environment. Bacillus velezensis is rich in metabolites, has broad-spectrum antibacterial activity and relatively strong anti-stress ability, and plays an increasingly important role in many fields such as agriculture, environment, fermentation industry, and the like. The bacillus velezensis WYJ-E14 has an extremely remarkable anti-tumor cell effect and has high application value in the development of biological anti-tumor drugs.
Disclosed in the present invention are a bipyridine ligand and amphiphilic rhombic supramolecular metal ring containing aggregation-induced emission (AIE) and aggregation-caused quenching (ACQ) groups and an application. A bipyridine ligand 1 containing AIE and ACQ groups and a diplatinum receptor 2 are dissolved in an alcohol solvent, and heating is performed at 40-60°C to react for 10-15 hours; and after the reaction is finished, post-treatment is performed to obtain an amphiphilic rhombic supramolecular metal ring 3. An application of the amphiphilic rhombic supramolecular metal ring containing the AIE and ACQ groups at 120°C as a fluorescent dye in biological imaging.
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
GREEN SYNTHESIS METHOD FOR ANTIBACTERIAL SUPERPOROUS HYDROGEL, PRODUCT THEREOF, AND USE THEREOF IN DEGRADATION OF VARIOUS POLLUTANTS IN WASTEWATER TREATMENT
Disclosed in the present invention are a green synthesis method for an antibacterial superporous hydrogel, a product thereof, and the use thereof in the degradation of various pollutants in wastewater treatment. A polyionic liquid superporous gel is prepared by means of the copolymerization of an imidazole ionic liquid bearing a double bond and a cross-linking agent containing a double bond. In a reaction system, water is a good solvent for a monomer ionic liquid and PEGDA, but is a poor solvent for a polyionic liquid. When the initial concentration of the ionic liquid is higher than 25%, a monomer phase rich in polyionic liquid gradually undergoes phase separation and microphase separation with water, and a water phase in a gel three-dimensional network structure, which is formed by the polyionic liquid and PEGDA, occupies a relatively large amount of space (the microphase separation process is beneficial for the formation of interpenetrating channels in the gel network structure). Finally, unreacted monomer ionic liquid is removed by using a pure-water dialysis method, and the moisture in a gel is then removed by using a freeze-drying method to ultimately obtain a macroporous or superporous hydrogel.
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
C08F 226/06 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
37.
CONJUGATION-FUSED BIPOLAR REDOX-ACTIVE MOLECULE, PREPARATION METHOD, AND APPLICATION THEREOF
The present disclosure discloses a conjugation-fused bipolar redox-active molecule and its preparation method and application. The bipolar redox-active molecule includes a p-type redox active center and an n-type redox active center. The p-type redox active center and the n-type redox active center are fused in a molecular unit by conjugation.
A cisplatin cross-linked protein hydrogel and a preparation method therefor. The main components of the hydrogel comprise the following components in mass content: 0.5-5.0% of drug, 6.0-50.0% of serum albumin, and 47.0-93.0% of solvent medium, wherein carboxyl on the surface of serum albumin and the drug form a coordinate covalent bond, and the drug is cisplatin. A hydrogel preparation is simple in structure and easy to prepare, and cisplatin is a cross-linking agent for promoting the formation of a protein hydrogel and is also an anti-tumor drug for achieving antitumor efficacy; and protein carboxyl limits release of cisplatin by means of a coordination function, so as to reduce a burst release behavior of a drug.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Disclosed are an HDAC/MAO-B dual inhibitor, the preparation thereof, and an application in the preparation of a drug and neuroprotective antioxidant for preventing and treating related diseases by inhibiting monoamine oxidase and histone deacetylase. The HDAC/MAO-B dual inhibitor has the following general formula (I) or (II): in the formulas (I) and (II): each R is independently an aromatic group or a substituted aromatic group. The HDAC/MAO-B dual inhibitor has both an HDAC inhibitory effect and an MAO-B inhibitory effect, being a multi-target hydroxamic acid/anthranilamide propargyl amine-type derivative that achieves neuroprotection and anti-oxidation by means of the synergy of a propynylamine group and hydroxamic acid or an anthranilamide group.
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07C 237/40 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to the field of medicinal chemistry. Disclosed in the present invention are a 14-chloro-β-elemene nitric oxide donor type derivative, preparation and application thereof in preparing an antitumor drug. The 14-chloro-β-elemene nitric oxide donor type derivative has a general formula as shown in formula (I). In the formula (I), R1is a straight chain or cyclic alcoholamine structure containing nitrogen and oxygen atoms; R2and R31-103-126-122-102-102-102-10 alkoxy. The derivative in the present invention is superior to a conventional β-elemene nitric oxide donor type derivative in terms of a design policy, an alcoholamine structure capable of improving the in vivo antitumor activity is introduced as a connecting arm, the in vivo stability is improved, and the derivative has good therapeutic activity on malignant brain glioma clinically lacking an effective therapeutic drug.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Disclosed are (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 2-bromo-2,2-difluoroacetate, a waterborne polyurethane, and preparation methods thereof. The (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 2-bromo-2,2-difluoroacetate could be used as a modified monomer for preparing a waterborne polyurethane, and substituents at a C2 position of the (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 2-bromo-2,2-difluoroacetate are two fluorine atoms and one bromine atom. When it is used for preparing the waterborne polyurethane, fluorine and bromine groups are introduced into the structure of the waterborne polyurethane, and the resultant waterborne polyurethane exhibits good moisture resistance and flame retardance.
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
B01J 31/04 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
B01J 31/12 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
C07D 317/24 - Radicals substituted by singly bound oxygen or sulfur atoms esterified
42.
DUAL-TARGETING BIOMIMETIC LIPOSOME CONTAINING ELEMENE AND CABAZITAXEL, AND PREPARATION METHOD THEREFOR AND USE THEREOF
A dual-targeting biomimetic liposome containing elemene and cabazitaxel. Every 100 mL of the dual-targeting biomimetic liposome containing elemene and cabazitaxel contains 0.15-0.75 g of elemene, 0.5-2.5 mL of absolute ethanol, 0.015-0.07 g of cabazitaxel, 0.25-1 g of oil, 0.25-1 g of a polyethylene glycol derivative, 1-5 g of a phospholipid, 0.05-0.2 g of cholesterol, 0.025-0.1 g of DSPE-PEG2000-transferrin, and 0.005-0.025 g of a tumor cell membrane protein, with the balance being water. The two drugs have a synergistic effect, such that the BBB permeability of the drugs and the uptake rate of the drugs by glioma cells are improved, and the toxic side effects of cabazitaxel and the irritation of elemene are also reduced. A method for preparing the liposome and the use of the liposome.
A privacy protection authentication method based on a wireless body area network may be applied to a smart home care system. The method provides an authentication method for two-way authentication and key verification between a device and a cloud server, can ensure identities of the device and the cloud server to be valid and prevent network information security from being affected by external invasion attacks. A physical unclonable function and an elliptic curve cryptography algorithm are introduced to encrypt key data in the authentication process, so that the whole authentication process is in a safe environment, and the security of the authentication process is further improved through adding and removing functions of a third-party identity. The privacy protection authentication protocol method can resist replay attacks and smart card impersonation attacks, the whole authentication process is safe and efficient, and has a high application value in smart home care scenes.
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
H04W 12/02 - Protecting privacy or anonymity, e.g. protecting personally identifiable information [PII]
A mat-type attention deficit hyperactivity disorder cognitive intervention training system, comprising: a program configuration module (1), used to configure a training mode and a parameter; a mat-type sensing module (2) which detects a change in an analog signal of a stepping pressure of a trainee, and is connected to the program setting module (1); a recording and transmission module (3), which converts the analog signal of the stepping pressure of the trainee into a digital signal, and recording a stepping time of the trainee, and which is connected to the mat-type sensing module (2); and a data analysis and presentation module (4), which performs training index evaluation of the trainee according to the signal transmitted by the recording and transmission module (3), and which is connected to the recording and transmission module (3) and the program configuration module (1). By means of a thin film pressure sensing component disposed in the device, a user may complete training by means of a stepping motion. User intervention training results are evaluated by means of collecting a reaction time signal of a reaction of the user stepping on a target, processing the same, and acquiring a periodic fluctuation feature in the target reaction time, making evaluation results more accurate.
Disclosed in the present invention are a cocaine esterase mutant and an application thereof. The cocaine esterase mutant is obtained by mutating a wild-type cocaine esterase, an amino acid sequence of the wild-type cocaine esterase being as shown in SEQ ID No. 1, the cocaine esterase mutant being T172R/G173Q/L196C/I301C, or with an additional V116K point mutation, or with an additional A51 point mutation, the A51 point mutation being to L, Y, V, F or W. Compared with the wild-type enzyme, the cocaine esterase mutant obtained by screening in the present invention has greatly improved catalytic efficiency for benzoylecgonine, a toxic metabolite of cocaine.
A modified biochar algae inhibitor, a use thereof, and a preparation method therefor. The modified biochar is obtained by modifying magnesium oxide-based biochar by means of ferroferric oxide. The modified biochar is used to perform algae inhibition and algal toxin adsorption, and raw materials are rich in source and cheap and easy to obtain. During algae inhibition, a solution can be quickly clarified and transparent, and a floc which has magnetism and is easy to sink is formed, such that recycling and reuse of the modified biochar are facilitated. In addition, the modified biochar can achieve effective algae inhibition without pretreatment of an algae solution during algae inhibition, such that time is less consumed, and the algae inhibition efficiency which is the same as or higher than that of an existing algae inhibition process is achieved.
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
C02F 1/28 - Treatment of water, waste water, or sewage by sorption
B01J 20/30 - Processes for preparing, regenerating or reactivating
47.
MULTI-SENSORY-MODALITY SUSTAINED ATTENTION MONITORING SYSTEM AND METHOD
A multi-sensory-modality sustained attention monitoring system and method. The monitoring system comprises a front-end monitoring device (1), a server (2), and a display terminal (3). The front-end monitoring device (1) is connected to the server (2) and used for setting and presenting a visual stimulus image or an auditory stimulus sound, receiving a button-press response, and acquiring video information of the state of a subject in a monitoring process. The server (2) performs data analysis according to the acquired user response signal and video information, and the server (2) is connected to the display terminal (3). The display terminal (3) is provided with a graphical display interface for playing back a video of the state of a user in the monitoring process. The monitoring system is simple in structure and convenient to use, comprises a visual modality and an auditory modality, and monitors the states of subjects by means of a video method while monitoring the subjects, thereby ensuring the effectiveness of the test. A periodic signal percentage is proposed as an index for monitoring sustained attention to characterize the hyperactivity of the subjects in different periods, more comprehensive and detailed information can be provided for sustained attention monitoring, and simultaneous monitoring of multiple persons is achieved.
A sustained attention regulation system for joint electroencephalogram and finger pressure feedback. The system is used for solving the problem that a subject of electroencephalogram feedback is difficult to enter a sustained attention state without a task. The system comprises: a finger pressure measurement module (1), a finger pressure sampling and transmission module (2), and a finger pressure conversion and recording module (3) which are connected in sequence; an electroencephalogram acquisition module (4) for acquiring an electroencephalogram analog signal of a subject; an electroencephalogram storage module (5) for converting the acquired electroencephalogram analog signal into a digital signal and storing the digital signal; an electroencephalogram data analysis module (6) for completing the analysis and extraction of an electroencephalogram feature signal according to the acquired electroencephalogram signal; and a joint feedback presentation module (7) for presenting the electroencephalogram feature signal and a finger pressure signal by means of visualization graphics. By means of a joint electroencephalogram and finger pressure feedback mode, a subject can quickly enter and maintain a sustained attention state, such that the sustained attention state of the subject can be accurately estimated.
An electroencephalogram feedback delay-based sustained attention regulation and control system. Said system comprises an electroencephalogram acquisition module (1) for acquiring an electroencephalogram analog signal of a subject; a data storage module (2) for converting the acquired electroencephalogram analog signal into a digital signal and storing same; a delay setting and parsing module (3) for setting a delay parameter and completing parsing and extraction of an electroencephalogram feature signal; and a feedback presentation module (4) for visually presenting the electroencephalogram feature signal. By setting a feedback delay time and feeding back an electroencephalogram feature signal to a subject after the feedback delay time, attention of the subject is adjusted, which conforms to the characteristics of sustained attention and attention deficits.
A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
A61B 5/375 - Electroencephalography [EEG] using biofeedback
50.
Efficient antifouling and hydrophilic polyethersulfone ultrafiltration membrane and preparation method thereof
60Co-γ radiation grafting chemical modification method, evenly distributing an ionic liquid on a surface of a polyethersulfone material, wherein the ionic liquid containing unsaturated bonds is connected with the polyethersulfone material through chemical bonds, and then obtaining an asymmetric porous membrane by the immersion-precipitation phase transformation method, and finally performing Soxhlet extraction on the porous membrane, so as to migrate the grafted ionic liquid from an interior of the porous membrane to a surface of the porous membrane to be enriched, so that the adsorption and antibacterial properties of the porous membrane are improved. A mass ratio of the ionic liquid to the polyethersulfone material is in a range of (2-11):100. The ultrafiltration membrane is an asymmetric porous membrane, and has excellent antifouling properties, good pure water flux and a good BSA retention rate.
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
51.
Method for preparing alkynyl 2-halo-2,2-difluoroacetate
Zhejiang Transfar Functional New Material Co., Ltd. (China)
Inventor
Zhang, Pengfei
Wang, Shengpeng
Li, Wanmei
Xu, Weiming
Chen, Bajin
Wang, Xiaojun
Abstract
A method for preparing alkynyl 2-halo-2,2-difluoroacetate is disclosed. The method comprises: subjecting a 2-halo-2,2-difluoro acetic acid, an alkynol, and a catalyst to an esterification reaction in a solvent, to obtain alkynyl 2-halo-2,2-difluoroacetate, wherein the catalyst includes one or more of sulfuric acid, phosphoric acid and p-toluenesulfonic acid.
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
C07C 69/63 - Halogen-containing esters of saturated acids
52.
Porous layered transition metal dichalcogenide and preparation method and use thereof
The present invention relates to the field of catalysts, and provides a porous layered transition metal dichalcogenide (TMD) and a preparation method and use thereof. The preparation method includes the following steps: (1) mixing silica microspheres, a transition metal salt and an elemental chalcogen, and pressing to obtain a tablet, the silica microspheres having a same or different particle diameters; and (2) sintering the tablet under hydrogen, and removing the silica microspheres to obtain the porous layered TMD. The porous layered TMD prepared by the method of the present invention has a high lattice edge exposure, which provides more active sites and higher catalytic activity, so the porous layered TMD can effectively catalyze the oxidation of alcohols to aldehydes or sulfides to sulfoxides under visible light irradiation.
C07C 45/29 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of hydroxy groups
C07C 315/02 - Preparation of sulfonesPreparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
C07C 317/10 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
53.
6H-imidazo[4,5,1-ij]quinolone, synthesis method and use thereof
50 values equivalent to anti-lung cancer drug osimertinib; these quinolone derivatives have a broad application prospect in the preparation of antitumor drugs. The 6H-imidazo[4,5,1-ij]quinolone provided by the present invention is of high research and application value and has potential application prospects in fields of pharmaceutical chemicals, materials, dyes, etc. The present invention uses thioquinolinamide as a raw material to synthesize 6H-imidazo[4,5,1-ij]quinolones, featuring simple operation, excellent selectivity, high yield, mild reaction conditions, and easy product separation.
C07D 215/00 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
C07D 221/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The disclosure provides processes for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile and for preparing sulindac, relating to the field of medicine. The former comprises mixing 6-fluoro-2-methyl-1-indanone, cyanoacetic acid, a first organic solvent and an acetic acid-based catalyst to proceed with a first condensation reaction to give a first condensation reaction solution, which contains 5-fluoro-2-methyl-3-indanacetonitrile; and mixing the first condensation reaction solution, per se, with a base, a second organic solvent and 4-(methylthio)benzaldehyde to proceed with a second condensation reaction to give 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile. The process is a one-pot process without separation of 5-fluoro-2-methyl-3-indanacetonitrile from the solvent, shortening the synthetic route, simplifying the preparation process and improving the 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile yield.
C07C 315/02 - Preparation of sulfonesPreparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
C07C 253/22 - Preparation of carboxylic acid nitriles by reaction of ammonia with carboxylic acids with replacement of carboxyl groups by cyano groups
C07C 317/46 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
C07C 255/35 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
55.
Quinolone derivatives, preparation methods and application thereof
A novel quinolone derivative and methods of its preparation are described in which the novel derivative comprises a diphenyl ether substituent on the nitrogen atom at the 1-position of the main quinolone ring. The novel derivative is shown to have antibacterial and anti-tumor cell activity.
C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
56.
ANTIFOULING AND HYDROPHILIC POLYETHERSULFONE ULTRAFILTRATION MEMBRANE AND PREPARATION METHOD THEREFOR
An antifouling and hydrophilic polyethersulfone ultrafiltration membrane and a preparation method therefor. By using a Co-γ radiation grafting chemical modification method, an unsaturated bond-containing ionic liquid linked by chemical bonds is uniformly distributed on the surface of polyethersulfone, and then an asymmetric porous membrane is prepared by using an immersion precipitation phase inversion method, a mass ratio of the ionic liquid to the polyethersulfone being 2-11:100. The ultrafiltration membrane is an asymmetric porous membrane, and has excellent antifouling properties, good pure water flux and a good BSA rejection rate.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
ZHEJIANG SHOUXIANGU BOTANICAL DRUG INSTITUTE CO., LTD (China)
Inventor
Lu, Jiangjie
Liu, Yuyang
Meng, Yijun
He, Jinyu
Li, Zhenhao
Wang, Huizhong
Kang, Jieyu
Abstract
Disclosed in the present invention is a group of molecular markers for identifying ganoderma sinense and ganoderma lucidum strains. The nucleotide sequences of the upstream primers GLMI001-F, GLMI002-F and GLMI003-F are respectively shown in SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5, and the nucleotide sequences of the downstream primers GLMI001-R, GLMI002-R and GLMI003-R are respectively shown in SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6. The present specific molecular markers GLMI001, GLMI002 and GLMI003 can be used for identifying and detecting ganoderma sinense and ganoderma lucidum strains.
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
The present invention provides a method for preparing a resveratrol compound, and belongs to the technical field of organic synthesis. In the present invention, first alkoxy-substituted benzyl halide, alkoxy-substituted benzaldehyde and a metal catalyst are subjected to oxidative addition and reduction elimination reactions to obtain alkoxy-substituted diphenylethanone; and then the alkoxy-substituted diphenylethanone and a metal catalyst are subjected to reduction, trans elimination and selective debenzylation reactions under a hydrogen atmosphere to obtain the resveratrol compound. In the preparation method of the present invention, the hydrogenation reduction, trans elimination and selective debenzylation reactions can be achieved just by a one-pot process, where the reaction directly obtains a trans olefin, thereby avoiding the formation of a isomer; and also the reaction selectively catalyzes debenzylation to eliminate Lewis acids from the source, and has the advantage of a high yield. Therefore, this process is a green and environmentally friendly process. The experimental results show that, the products obtained by the preparation method as provided by the present invention are all trans olefins, with the purity being up to more than 99.5%, and each yield being greater than 80%.
C07C 37/20 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms using aldehydes or ketones
C07C 37/84 - SeparationPurificationStabilisationUse of additives by physical treatment by crystallisation
C07C 37/60 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by oxidation reactions introducing directly a hydroxy group on a CH-group belonging to a six-membered aromatic ring with the aid of other oxidants than molecular oxygen or their mixtures with molecular oxygen
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C 45/45 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by condensation
The present invention provides a method for preparing levobunolol hydrochloride. In the present invention S-1-tert-butyl-epoxy methylamine is subjected to a substitution reaction with 5-hydroxy-1-tetralone, and acidified to obtain the target product levobunolol hydrochloride. The method provided by the present invention greatly improves the regioselectivity of the reaction, avoids the occurrence of side reactions, and effectively improves the yield and optical purity of levobunolol hydrochloride, with the yield being 87.3%, and the ee value being over 99%.
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
60.
MEDICAL USE OF E3 LIGASE FBW7 IN DELAYING AGING AND RELATED DISEASES
Disclosed is a use of E3 ligase FBW7 in preparing a drug for delaying aging and for preventing and treating aging-related diseases by means of inhibiting telomere damage, wherein the amino acid sequence of the FBW7 is as shown in SEQ. No.2. Knockout or RNA interference inhibiting the gene expression of the FBW7, a gene mutant expressing the FBW7 competitively inhibiting the FBW7 protein, or the overexpression of TPP1 overcoming the degradation caused by the FBW7 can protect the chromosome telomere from damage caused by stress, such as radiation, bleomycin and hydrogen peroxide, prevent the degradation of TPP1 in the basic state or in the stress state, result in the effect of extending telomere length, increase the number of tissue stem cells, improve the pulmonary respiratory function in the basic state, and prevent the occurrence of lung tissue aging and pulmonary fibrosis in the stress state, and same can be used in preparing a drug for preventing and treating telomere dysfunction to provide ideas and means for anti-aging.
A61P 39/06 - Free radical scavengers or antioxidants
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
61.
Core-shell structure supported tungsten composite catalyst and preparation method and use thereof
4, is used to catalyze and synthesize quinolone compounds. The present invention provides an efficient preparation method of quinolone compounds using a catalyst which can be recovered by magnetic separation and recycled. The catalyst prepared by the present invention can be reused in the preparation of quinolone compounds and still retains the original activity without deactivation, which not only greatly improves the production efficiency, but also reduces the environmental pollution.
C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
62.
Series of resveratrol-derivative fluorescently labeled molecules and synthesis method thereof
The invention discloses a series of resveratrol-derivative fluorescently labeled molecules and a synthesis method thereof. The fluorescently labeled molecules has a molecular formula as shown in formula (I). The synthesis method includes the steps of adding a certain amount of resveratrol derivative and solvent in a reaction vessel, adding a fluorescent marker as shown in formula (III) and a certain amount of alkali, reacting at 20° C.-60° C. for 2-10 hours, and after the reaction is completed, spin-drying the reaction solvent and performing post-processing to obtain the products.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
patents
